Hunan Yuantai Biotechnology Co., Ltd. was established in 2001 with a registered capital of 122.1364 million yuan. It is the only high-tech enterprise in the province to establish an R&D center in Silicon Valley, USA, dedicated to the large-scale production of monoclonal antibodies through genetic engineering and protein engineering, as well as the research and development of immunological diagnostic technologies and targeted drugs.
The company has built a leading, globally renowned antibody technology platform covering mouse, rabbit, and human antibodies, and has carried out businesses including scientific research antibody products, CAR-T technology CRO and CDMO services, and global antibody target and immunotherapy patent licensing. It has developed more than 6,000 kinds of mouse-derived monoclonal antibodies (over 50,000 hybridoma cell lines), and has long provided OEM services for top international biotech companies such as Sigma, Abcam, and Fisher. In 2020, it led the drafting of the group standard "General Technical Regulations for Mouse Monoclonal Antibodies," further establishing its leading position in the domestic monoclonal antibody production field. It is the Provincial Experimental Animal-Derived Antibody Engineering Technology Research Center, the Municipal Antibody and Immunotherapy Engineering Technology Research Center, and the Municipal Development and Reform Commission Enterprise Technology Center.
Its wholly-owned U.S. subsidiary ProMab Biotechnologies is mainly engaged in innovative antibody technology research and development. It is the first CAR-T CRO service enterprise in the United States, occupying 80% of the U.S. CAR-T CRO service market, and has provided nearly 400 high-quality services to dozens of major pharmaceutical companies, R&D centers, and universities worldwide.
The company has applied for nearly 36 PCT or U.S. invention patents, and has carried out intellectual property commercial cooperation with more than ten internationally and domestically renowned companies such as NantKwest (a NASDAQ-listed company). Multiple tumor cell immunotherapy projects have entered exploratory clinical trials in several top-tier hospitals in China. In the next three years, it will invest 300-500 million yuan, and the launch of proprietary cell drugs is just around the corner.
What does Hunan Yuantai Biotechnology Co., Ltd. require? Who is Yuantai Biotech hiring? Yuantai Biotech recruitment: 销售类占比最多占64.3%，其次是科研类占42.9%. What education can get in at Yuantai Biotech? 本科占比最多占57.1%，其次是硕士占21.4%. High education required at Yuantai Biotech? 硕士占21.4%. Work experience required at Yuantai Biotech? 1-3年占比最多占42.9%，其次是3-5年占42.9%. Where are the job locations at Yuantai Biotech? 长沙占比最多占85.7%，其次是长春占7.1%. Based on job postings from the past year, for reference only.
Provided by
Congratulations, submitted successfully!
Your edit is under review. You will be notified by email within 1 business day.
Submission failed.
Help others learn about this company, add my impression of this company»
Log in with the following accounts to save your follows
Jobui does not provide an APP. Please follow our WeChat official account.
